[Skip to Content]
[Skip to Content Landing]
February 17, 1993

Researchers Try New Definitions, New Therapies in Effort to Solve Growing Problem of Sepsis

JAMA. 1993;269(7):838-843. doi:10.1001/jama.1993.03500070014003

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


PRELIMINARY but promising results of a phase 2 trial of a therapy for sepsis were reported at the 32nd annual Interscience Conference on Antimicrobial Agents and Chemotherapy, held in Anaheim, Calif.

Although the nonblinded study involved a small number of patients, the researchers are encouraged by the strong dose response seen and are looking forward to analyzing the results of a larger, multicenter phase 3 trial just completed.

At the conference, which was sponsored by the American Society for Microbiology, Steven M. Opal, MD, associate professor of medicine, Brown University School of Medicine, Providence, RI, reported the results of the phase 2 trial of a recombinant interleukin 1 receptor antagonist (IL-1ra). The nonblinded, prospective trial involved 99 patients with severe sepsis or septic shock who were randomly divided into a placebo group and three treatment groups, each with approximately 25 patients.

The day before he presented his data at the